標(biāo)題: Titlebook: Advances in Breast Cancer Management; William J. Gradishar,William C. Wood Book 2008Latest edition Springer-Verlag US 2008 BRCA.adjuvant t [打印本頁] 作者: 我要黑暗 時(shí)間: 2025-3-21 19:32
書目名稱Advances in Breast Cancer Management影響因子(影響力)
書目名稱Advances in Breast Cancer Management影響因子(影響力)學(xué)科排名
書目名稱Advances in Breast Cancer Management網(wǎng)絡(luò)公開度
書目名稱Advances in Breast Cancer Management網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Advances in Breast Cancer Management被引頻次
書目名稱Advances in Breast Cancer Management被引頻次學(xué)科排名
書目名稱Advances in Breast Cancer Management年度引用
書目名稱Advances in Breast Cancer Management年度引用學(xué)科排名
書目名稱Advances in Breast Cancer Management讀者反饋
書目名稱Advances in Breast Cancer Management讀者反饋學(xué)科排名
作者: Biofeedback 時(shí)間: 2025-3-21 22:24
Sentinel Lymphadenectomy in Breast Cancer,welche Interventionen und Therapieelemente für RaucherInnen, abstinenzmotivierte RaucherInnen, für konsonante RaucherInnen und für RaucherInnen, die erst seit kurzer Zeit abstinent sind, für die Praxis evidenzbasiert empfohlen werden konnen. Zu Beginn wird eine Zusammenfassung sowohl zu spezifischen作者: agonist 時(shí)間: 2025-3-22 04:19 作者: Licentious 時(shí)間: 2025-3-22 05:17
Overview of Randomized Trials of Systemic Adjuvant Therapy,d to be a reference and further study guide for cooks, chefs, dietitians, and foodservice management personnel who are already employed in this important industry. There are many texts available that thoroughly cover, in great depth, the chemistry and technical aspects of fats and oils. However, the作者: 只有 時(shí)間: 2025-3-22 09:36
New Tools for Assessing Breast Cancer Recurrence,h dar.Gibt einen überblick zu Gestaltung und Management von Dieses Buch soll ein Bewusstsein wecken hinsichtlich der Notwendigkeit und Vorteile von innerbetrieblichen (technischen) Standards: Jedes Unternehmen hat das Ziel, effizient, innovativ und wirtschaftlich zu produzieren. Für eine effiziente 作者: Lamina 時(shí)間: 2025-3-22 13:40
Development of New Targeted Therapies for Breast Cancer,rbeitsbedingte Gesundheitsgefahren und deren Pr?vention in unserer Gesellschaft und in Unternehmen nicht rein politischer Fragen sein. Die Wissenschaften sind hier aufgerufen ihr Fachwissen einzubringen und sich für interdiszipli?re Zusammenarbeit zu bef?higen und ihr Wissen in Unternehmen an den Be作者: mechanical 時(shí)間: 2025-3-22 17:26
New Radiation Treatment Strategies for Early Stage Breast Cancer,en, eine zun?chst unübersehbar gro?e Zahl von Menschen get?tet und verletzt worden war, erkl?rte die spanische Regierung die baskische Terrororganisation ETA zweifelsfrei zu T?tern. Obgleich seit dem Mittag des gleichen Tages die Hinweise auf einen islamistischen Hintergrund sich verdichteten, blieb作者: 驚呼 時(shí)間: 2025-3-22 23:33
Breast Cancer Prevention,has two monochromators or alternative wavelengthselection devices. The excitation monochromator (M1) selects the wavelength of the light with which the sample is to be irradiateci, and the emission monochromator (M2) selects the wavelength of fluorescence (or scattered light or phosphorescence, etc.作者: Rejuvenate 時(shí)間: 2025-3-23 02:11
Back Mattereatitis (AP). Computed tomography (CT) with contrast enhancement (CECT) [1] and ultrasonography (US) [2] are examples of recent diagnostic techniques which, along with clinical assement of the patient, provide the basis for a decision on therapy. CECT and US are usually not available in the emergenc作者: Magisterial 時(shí)間: 2025-3-23 06:07
Book 2008Latest editione being better characterized thru laboratory investigation and as a result of this work numerous novel therapeutics that target these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some 作者: 膽小懦夫 時(shí)間: 2025-3-23 10:02 作者: Vulnerable 時(shí)間: 2025-3-23 15:51 作者: AXIS 時(shí)間: 2025-3-23 21:35 作者: exquisite 時(shí)間: 2025-3-24 01:36
Overview of Randomized Trials of Systemic Adjuvant Therapy,g. Tested quantity recipes are included as a further guide to product usage and menu expansion. This book is divided into three parts. The first part deals with the chemistry and general technical background for fats and oils. Part II covers the major practical applications in foodservice, along wit作者: FLOUR 時(shí)間: 2025-3-24 05:16 作者: Supplement 時(shí)間: 2025-3-24 07:49
New Radiation Treatment Strategies for Early Stage Breast Cancer,genen Truppen in den Irak geh?rte; was von einer gro?en Mehrheit der spanischen Bev?lkerung mit Vehemenz abgelehnt worden war. Eine islamistische T?terschaft hingegen würde den Anschlag als Folge eben dieser Beteiligung erscheinen lassen und alle Gründe und Stimmungen gegen die Beteiligung am Irak-K作者: bisphosphonate 時(shí)間: 2025-3-24 11:41 作者: 陶醉 時(shí)間: 2025-3-24 17:51 作者: floaters 時(shí)間: 2025-3-24 22:40 作者: 中世紀(jì) 時(shí)間: 2025-3-25 01:28 作者: 改變 時(shí)間: 2025-3-25 04:06
An Architecture for HCI in Real-time Systemse adjuvant treatment strategy for many women with early stage disease. Over the last several decades, investigators have endeavored to optimize disease specific outcomes and thus, improve patient survival through therapeutic innovation, while minimizing treatment-related toxicity. These efforts have作者: 詩集 時(shí)間: 2025-3-25 10:33 作者: avenge 時(shí)間: 2025-3-25 11:54
https://doi.org/10.1007/978-1-4471-3548-7ctomy into clinical practice in 18961. While hormonal therapy is not traditionally categorized as targeted therapy, the estrogen receptor remains arguably the most important growth factor receptor identified for breast cancer, as adjuvant hormonal therapies have a bigger impact on recurrence and sur作者: BROOK 時(shí)間: 2025-3-25 19:28 作者: Ambulatory 時(shí)間: 2025-3-25 22:41
0927-3042 these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some 978-0-387-78812-8978-0-387-73161-2Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: 不斷的變動 時(shí)間: 2025-3-26 01:29 作者: Dedication 時(shí)間: 2025-3-26 08:20 作者: Affection 時(shí)間: 2025-3-26 08:58
Harold Thimbleby,Andy Cockburn,Steve Jonescer subtypes, as well as the various molecular signatures with their prognostic and predictive implications. Two prospective randomized trials, MINDACT and TAILORx, designed to validate this new technology, will be briefly discussed.作者: anus928 時(shí)間: 2025-3-26 12:50
Book 2008Latest editionade in the laboratory to new treatment strategies, the outcome of breast cancer patients with both early and late stage disease has continued to improve. This volume will highlight many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer...作者: 莎草 時(shí)間: 2025-3-26 17:37 作者: BOLT 時(shí)間: 2025-3-27 00:10 作者: padding 時(shí)間: 2025-3-27 03:18 作者: 冥界三河 時(shí)間: 2025-3-27 07:37
978-0-387-78812-8Springer-Verlag US 2008作者: somnambulism 時(shí)間: 2025-3-27 11:20
Advances in Breast Cancer Management978-0-387-73161-2Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: Pudendal-Nerve 時(shí)間: 2025-3-27 15:06 作者: persistence 時(shí)間: 2025-3-27 18:38
Defining the Intelligent System’s Goalsst cancer cases were diagnosed. It is estimated that close to 50,000 women died of the same disease in 2006. Breast cancer develops in about 12% of women who live to age 90. A positive family history is reported by 15-20% of women with breast cancer. Studies of twins suggest that heritable factors a作者: COM 時(shí)間: 2025-3-27 23:01
The Components of Intelligent Experiencesng mammography guidelines between 1980 and 1987, there was a doubling in the incidence of small breast cancers (≤ 2 cm) with a concomitant decrease by 27% in the incidence of larger breast cancers (≥ 3 cm). As a greater percentage of breast cancers are being diagnosed at an earlier stage, the medica作者: aggravate 時(shí)間: 2025-3-28 03:45 作者: 輕快走過 時(shí)間: 2025-3-28 10:02
Trevor P. Hopkins,Steve K. Wallis elucidated the impact of adjuvant chemotherapy for breast cancer. Several trials have confirmed the promise of aromatase inhibitors for adjuvant endocrine therapy. A new targeted therapy, trastuzumab, has been shown to be highly effective as part of adjuvant therapy for HER2-positive breast cancer.作者: 殺子女者 時(shí)間: 2025-3-28 12:59
HyperCard: An Object-Oriented Disappointments a means of improving resectability and locoregional control. This treatment sequence has now become standard, conventional practice for patients with bulky cancers of the breast and axillae. Two important advantages identified from this experience have resulted in extension of the neoadjuvant ther作者: thrombus 時(shí)間: 2025-3-28 15:16 作者: doxazosin 時(shí)間: 2025-3-28 20:50
https://doi.org/10.1007/978-1-4471-3548-7 therapy. Though this simple approach served well for decades, the recent development of trastuzumab showed its inadequacies. Trastuzumab, neither broadly cytotoxic nor a classic hormonal manipulation, didn’t fit. Thus, a third category, biologic therapy, or alternatively, targeted therapy, emerged.作者: 積極詞匯 時(shí)間: 2025-3-29 00:48
Kenneth R. Baker,Dartmouth Collegeof breast cancer was one of the great success stories of twentieth-century oncology. Approximately 70-80% of patients with stage I or II invasive breast cancers are estimated to be potential candidates on technical grounds for BCT.
